Construct: ORF TRCN0000471916
Construct Description:
- Construct Type:
- ORF
- Other Identifiers:
- ORF013395.1_s317c1
- Derived from:
- ccsbBroadEn_11604
- DNA Barcode:
- TGTCACCTTGGTTTGGGTTGGTTC
- Epitope Tag:
- V5
- Notes:
- No stop codon in insert
Originally Annotated References:
- Gene:
- RABL2B (11158)
Vector Information:
- Vector Backbone:
- pLX_317
- Pol II Cassette 1:
- SV40-PuroR
- Pol II Cassette 2:
- EF1a-TRCN0000471916
- Selection Marker:
- PuroR
- Visible Reporter:
- n/a
- Epitope Tag:
- V5
Current transcripts matched by this ORF:
Taxon | Gene | Symbol | Description | Transcript | Nuc. Match %[?]A simple nucleotide-based global alignment percentage, calculated as follows: total nt. matches ---------------------------------- aligned length (incl. gaps) |
Prot. Match %[?]A simple amino acid-based global alignment percentage, calculated as follows: total aa. matches ---------------------------------- aligned length (incl. gaps) |
Match Diffs[?]This field may contain sequence annotations in HGVS format. For more information about HGVS annotations, please refer to the HGVS Quick Reference Guide. | |
---|---|---|---|---|---|---|---|---|
1 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028559.2 | 85.3% | 85.3% | 298_348del |
2 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003234.1 | 59.1% | 45% | (many diffs) |
3 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354424.2 | 52.6% | 43.6% | (many diffs) |
4 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306161.2 | 52.1% | 43.3% | (many diffs) |
5 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354421.2 | 52.1% | 43.3% | (many diffs) |
6 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354423.2 | 52.1% | 43.3% | (many diffs) |
7 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003226.1 | 52.1% | 43.3% | (many diffs) |
8 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354418.2 | 51.5% | 40.9% | (many diffs) |
9 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354419.2 | 51.5% | 40.9% | (many diffs) |
10 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003223.1 | 51.5% | 40.9% | (many diffs) |
11 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354417.2 | 43.7% | 43.7% | (many diffs) |
12 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130922.3 | 43.4% | 43.4% | 298_684del |
13 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350005.2 | 43.4% | 43.4% | 298_684del |
14 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350006.2 | 43.4% | 43.4% | 298_684del |
15 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350007.2 | 43.4% | 43.4% | 298_684del |
16 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_007081.4 | 43.4% | 43.4% | 298_684del |
17 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028556.1 | 43.4% | 43.4% | 298_684del |
18 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001003789.3 | 43.2% | 43.2% | 298_687del |
19 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130919.3 | 43.2% | 43.2% | 298_687del |
20 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130920.3 | 43.2% | 43.2% | 298_687del |
21 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130921.3 | 43.2% | 43.2% | 298_687del |
22 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350003.2 | 43.2% | 43.2% | 298_687del |
23 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350004.2 | 43.2% | 43.2% | 298_687del |
24 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028552.1 | 43.2% | 43.2% | 298_687del |
25 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028555.1 | 43.2% | 43.2% | 298_687del |
26 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_024452147.1 | 43.2% | 43.2% | 298_687del |
27 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354416.2 | 42.9% | 42.9% | (many diffs) |
28 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_007082.5 | 42.9% | 42.9% | (many diffs) |
29 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_013412.4 | 42.9% | 42.9% | (many diffs) |
30 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003220.1 | 42.9% | 42.9% | (many diffs) |
31 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003222.1 | 42.9% | 42.9% | (many diffs) |
32 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306158.2 | 42.7% | 42.7% | (many diffs) |
33 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306159.2 | 42.7% | 42.7% | (many diffs) |
34 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354412.2 | 42.7% | 42.7% | (many diffs) |
35 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354413.2 | 42.7% | 42.7% | (many diffs) |
36 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354414.2 | 42.7% | 42.7% | (many diffs) |
37 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003213.1 | 42.7% | 42.7% | (many diffs) |
38 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003214.1 | 42.7% | 42.7% | (many diffs) |
39 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003215.1 | 42.7% | 42.7% | (many diffs) |
40 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003216.1 | 42.7% | 42.7% | (many diffs) |
41 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452575.1 | 42.7% | 42.7% | (many diffs) |
42 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028551.1 | 42.3% | 42.3% | 298_702del |
43 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350016.2 | 42.1% | 42.1% | 298_705del |
44 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350017.2 | 42.1% | 42.1% | 298_705del |
45 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003212.1 | 41.8% | 41.8% | (many diffs) |
46 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003210.1 | 41.7% | 41.7% | (many diffs) |
47 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003211.1 | 41.7% | 41.7% | (many diffs) |
48 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001130923.3 | 41.5% | 41.5% | 298_714del |
49 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350013.2 | 41.5% | 41.5% | 298_714del |
50 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350014.2 | 41.5% | 41.5% | 298_714del |
51 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350015.2 | 41.5% | 41.5% | 298_714del |
52 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028547.1 | 41.5% | 41.5% | 298_714del |
53 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350008.2 | 41.4% | 41.4% | 298_717del |
54 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350009.2 | 41.4% | 41.4% | 298_717del |
55 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350010.2 | 41.4% | 41.4% | 298_717del |
56 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350011.2 | 41.4% | 41.4% | 298_717del |
57 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | NM_001350012.2 | 41.4% | 41.4% | 298_717del |
58 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028543.1 | 41.4% | 41.4% | 298_717del |
59 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028544.1 | 41.4% | 41.4% | 298_717del |
60 | human | 11158 | RABL2B | RAB, member of RAS oncogene... | XM_017028546.1 | 41.4% | 41.4% | 298_717del |
61 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001306160.3 | 41.1% | 41.1% | (many diffs) |
62 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354410.2 | 41.1% | 41.1% | (many diffs) |
63 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_024452573.1 | 41.1% | 41.1% | (many diffs) |
64 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354405.2 | 41% | 41% | (many diffs) |
65 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354406.2 | 41% | 41% | (many diffs) |
66 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354407.2 | 41% | 41% | (many diffs) |
67 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354408.2 | 41% | 41% | (many diffs) |
68 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NM_001354409.2 | 41% | 41% | (many diffs) |
69 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712208.3 | 41% | 41% | (many diffs) |
70 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_006712209.3 | 41% | 41% | (many diffs) |
71 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_011510509.2 | 41% | 41% | (many diffs) |
72 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003203.1 | 41% | 41% | (many diffs) |
73 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003204.1 | 41% | 41% | (many diffs) |
74 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003205.1 | 41% | 41% | (many diffs) |
75 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XM_017003207.1 | 41% | 41% | (many diffs) |
76 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148879.2 | 14.5% | (many diffs) | |
77 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148882.2 | 14.4% | (many diffs) | |
78 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148881.2 | 14.4% | (many diffs) | |
79 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | NR_148880.2 | 13.3% | (many diffs) | |
80 | human | 11159 | RABL2A | RAB, member of RAS oncogene... | XR_002959036.1 | 11.7% | (many diffs) | |
81 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521326.3 | 38.4% | 39.1% | (many diffs) |
82 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | NM_026817.3 | 38.2% | 39% | (many diffs) |
83 | mouse | 68708 | Rabl2 | RAB, member RAS oncogene fa... | XM_006521327.3 | 25.1% | 27.3% | (many diffs) |
Sequence Information
Note: uppercase bases indicate empirically verified sequence.
- ORF start:
- 157
- ORF end:
- 454
- ORF length:
- 297
- Sequence:
-
1 GGCACTTGAT GTAATTCTCC TTGGAATTTG CCCTTTTTGA GTTTGGATCT TGGTTCATTC 61 TCAAGCCTCA GACAGTGGTT CAAAGTTTTT TTCTTCCATT TCAGGTGTCG TGAGGCTAGC 121 ATCGATTGAT CAACAAGTTT GTACAAAAAA GTTGGCATGG CAGAAGACAA AACCAAACCG 181 AGTGAGTTGG ACCAAGGGAA GTATGATGCT GATGACAACG TGAAGATCAT CTGCCTGGGA 241 GACAGCGCAG TGGGCAAATC CAAACTCATG GAGAGATTTC TCATGGATGG CTTTCAGCCA 301 CAGCAGCTGT CCACGTACGC CCTGACCCTG TACAAGCACA CAGCCACGGT AGATGGAAGG 361 ACCATCCTTG TGGACTTTTG GGACACGGCA GGCCAGGAGC GGTTCCAGAG CATGCATGCC 421 TCCTACTACC ACAAGGCCCA CGCCTGCATC ATGTGCCCAA CTTTCTTGTA CAAAGTGGTT 481 GATATCGGTA AGCCTATCCC TAACCCTCTC CTCGGTCTCG ATTCTACGTA GTAATGAACT 541 AGTCCGTAAC TTGAAAGTAT TTCGATTTCT TGGCTTTATA TATCTTGTGG AAAGGACGAT 601 GTCACCTTGG TTTGGGTTGG TTCACGCGTT AAGTCgacaa tcaacctctg gattacaaaa 661 tttgtgaaag att